COX inhibition with anti-PD-1 in advanced dMMR colorectal cancer: Improving antigen presentation?

Benoit Rousseau; Paul Johannet

doi:10.1016/j.medj.2024.06.009

COX inhibition with anti-PD-1 in advanced dMMR colorectal cancer: Improving antigen presentation?

Med. 2024 Aug 9;5(8):839-841. doi: 10.1016/j.medj.2024.06.009.

Authors

Benoit Rousseau¹, Paul Johannet²

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: [email protected].
² Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 39127029
DOI: 10.1016/j.medj.2024.06.009

Abstract

dMMR tumors, which have high tumor mutational and neoantigen burdens, are highly responsive to immune checkpoint blockade. Wu et al.¹ showed that combining COX inhibitors with PD-1 blockade could be a safe and effective treatment option for dMMR metastatic colorectal cancer. The study highlights the potential of this combination therapy in achieving deep and long-lasting responses in dMMR colorectal cancers.

MeSH terms

Antigen Presentation / drug effects
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / immunology
Colorectal Neoplasms* / pathology
Cyclooxygenase Inhibitors / pharmacology
Cyclooxygenase Inhibitors / therapeutic use
Humans
Immune Checkpoint Inhibitors* / pharmacology
Immune Checkpoint Inhibitors* / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

Immune Checkpoint Inhibitors
Cyclooxygenase Inhibitors
Programmed Cell Death 1 Receptor